Tom Greene

11PUBLICATIONS
54CO-AUTHORS
Molecular targetsCardiology (incl. cardiovascular diseases)Image processingRural community developmentPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 21, 2026
Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk.

Sydney E Hartsell, Guo Wei, Ravinder Singh

|Sep 04, 2025
Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.

Lesley A Inker, Brendon L Neuen, Wendy McCallum

|Jul 28, 2025
Population-Based Digital Health Interventions to Deliver at-Home COVID-19 Testing: SCALE-UP II Randomized Clinical Trial.

Guilherme Del Fiol, Tatyana V Kuzmenko, Brian Orleans

|Jan 23, 2024
Role of Age and Competing Risk of Death in the Racial Disparity of Kidney Failure Incidence after Onset of CKD.

Guofen Yan, Robert Nee, Julia J Scialla

|Mar 15, 2023
Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD.

Hiddo J L Heerspink, Lesley A Inker, Hocine Tighiouart

|Aug 17, 2022
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.

Niels Jongs, Glenn M Chertow, Tom Greene

Pageof 2